They’ll also receive one tradeable contingent value right for each Celgene share, allowing the holder to receive a payment when future regulatory milestones are hit.
Original source: https://health.economictimes.indiatimes.com/news/pharma/bristol-myers-squibb-buying-celgene-in-usd-74-bn-deal/67375060?utm_source=RSS&utm_medium=ETRSS
